| Filed On | Filing |
|---|---|
| 06 Aug 2026 | FORM 15-12G |
| 31 Jul 2026 | FORM S-8 POS |
| 31 Jul 2026 | SCHEDULE 13G |
| 30 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +8 more
as Revolving Administrative Agent, the Swingline Lender and an L/C Issuer |
| 28 Jul 2026 |
Form 4: Delgado Sigfrido, SVP, Operations
Returned 110,627 shares to the issuer ($2.77M) · Received 54,886 shares as a grant or award · Disposed of 59,434 Employee Stock Option (right to buy) (Disposition to Issuer) |
| 28 Jul 2026 |
Form 4: Galovan Scott Michael, SVP, Chief Financial Officer
Returned 231,717 shares to the issuer ($5.79M) · Received 96,121 shares as a grant or award · Disposed of 90,668 Employee Stock Option (right to buy) (Disposition to Issuer) |
| 28 Jul 2026 |
Form 4: Pacitti David, Chief Executive Officer
Returned 766,924 shares to the issuer ($19.2M) · Received 444,730 shares as a grant or award · Disposed of 239,354 Employee Stock Option (right to buy) (Disposition to Issuer) |
| 28 Jul 2026 |
Form 4: Shimer Julie Ann, Director
Returned 50,090 shares to the issuer ($1.25M) · Disposed of 12,003 Restricted Share Units (Disposition to Issuer) ($300K) |
| 28 Jul 2026 |
Form 4: Oleary Patrick J, Director
Returned 54,640 shares to the issuer ($1.37M) · Disposed of 12,003 Restricted Share Units (Disposition to Issuer) ($300K) |
| 28 Jul 2026 |
Form 4: Franchini Indrani Lall, Director
Returned 4,817 shares to the issuer ($120K) · Disposed of 12,003 Restricted Share Units (Disposition to Issuer) ($300K) |
| 28 Jul 2026 |
Form 4: Egbuonu-Davis Lisa, Director
Returned 13,811 shares to the issuer ($345K) · Disposed of 12,003 Restricted Share Units (Disposition to Issuer) ($300K) |
| 28 Jul 2026 |
Form 4: Blackford Gary, Director
Returned 119,590 shares to the issuer ($2.99M) · Disposed of 12,003 Restricted Share Units (Disposition to Issuer) ($300K) |
| 27 Jul 2026 | 25-NSE |
| 22 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
ALPHARETTA, GA – July 22, 2026 – Avanos Medical, Inc. (NYSE: AVNS) (“Avanos” or the “Company”), a leading medical technology company, today announced that its stockholders have voted to approve the pending acquisition of Avanos by affili... |
| 15 Jul 2026 | DEFA14A |
| 15 Jul 2026 |
8-K: Other Events
As previously disclosed, on April 13, 2026, Avanos Medical, Inc. (“Avanos” or the “Company”) entered into an Agreement and Plan of Merger (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with it... |
| 02 Jul 2026 | DEFA14A |
| 02 Jul 2026 |
8-K: Regulation FD Disclosure
ALPHARETTA, GA and NEW YORK, NY – July 2, 2026/PRNewswire/ – Avanos Medical, Inc. (NYSE: AVNS) (“Avanos”) and American Industrial Partners (“AIP”) jointly announced the receipt of all required regulatory approvals to complete the pending... |
| 10 Jun 2026 | DEFM14A |
| 01 Jun 2026 | FORM SD |
Loading...